Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals


This edition of our ongoing Better Buy series pits two marijuana stocks -- GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) -- against each other. Rather than growing plants to sell, both companies are taking the more regulated path of developing drugs approved by the Food and Drug Administration from active compounds that are in marijuana or related to them.

In fact, GW Pharmaceuticals' CEO Justin Gover would rather his company not be called a cannabis stock. And Corbus' lead compound is synthesized so marijuana plants aren't even involved, although it's based on cannabinoids, the active class of compounds in marijuana.

GW Pharmaceuticals gained FDA approval last year for its cannabidiol drug Epidiolex to treat a pair of childhood epilepsies called Dravet syndrome and Lennox-Gastaut syndrome (LGS). Third-quarter sales came in at $86.1 million, up almost 26% from second-quarter sales.

Continue reading


Source Fool.com

Like: 0
Share

Comments